NeuroNetworks Fund
402 Main St, New Canaan, CT, 06840, United States
Overview
NeuroNetworks Fund is a venture fund investing in innovative treatments for autism, epilepsy and schizophrenia. The Fund helps to fill the gap between government funding, which has grown scarcer in recent years and private capital that has become more risk adverse regarding drug development in the neurodisease sector. Under this model, the Fund will begin a major philanthropic fund-raising campaign and use the charitable donations to invest in entrepreneurial companies developing new drugs and diagnostics. All investment returns then will be recycled to allow to the Fund to continue its charitable mission and become self-sustaining.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Mindnest Health
Led · Seed · Apr 2020
MindNest Health develops a digital parent‑training platform that teaches skills and techniques typically available only from top child behavioral health centers. The company’s tools target families of children with autism and other behavioral conditions to expand access where proximity and long wait times limit care. MindNest was founded by David Grodberg, M.D., a Medical Director at the Yale Child Study Center, and is led by CEO Lauren Belliveau. The company says the COVID‑19 pandemic has increased demand for digital health solutions and that these funds will help advance the platform toward commercialization. MindNest was founded in New Haven and intends to grow there to leverage Yale and the local tech community. The seed financing will allow the team to move the digital parent‑training program into beta testing.
Team
No current team members are available.